Clinical Policy: Sunvozertinib (Zegfrovy)
Customize your policy alerts
Sign up for mhn Policy CP.PHAR.742 alerts
Get alerted when Policy CP.PHAR.742 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity criteria and prior authorization requirements for sunvozertinib (Zegfrovy) for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations; applies to members covered by the payer's Commercial, HIM, and Medicaid lines of business.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.